<DOC>
	<DOCNO>NCT01447680</DOCNO>
	<brief_summary>The purpose study compare result HIV and/or Hepatitis C Virus antibody test use routine plasma versus SMARTplasma blood sample . SMARTplasma enrich antibody via stimulation step whole blood SMARTube™ ( SMARTstim™ USA ) .</brief_summary>
	<brief_title>Comparison Plasma &amp; SMARTplasma Human Immunodeficiency Virus ( HIV ) Hepatitis C Virus ( HCV ) Antibody Testing</brief_title>
	<detailed_description>Following exposure HIV HCV , `` window period '' person infect virus produce antibody high enough level detect antibody detection test method . During time , person capable unknowingly transmit virus others . SMARTstim ( SMARTube ) blood sample additive pre-treats blood , stimulate antibody production vitro bring detectable level use ELISA ( antibody test method ) . Accelerated antibody production allow antibody detection specimen would otherwise detectable limit antibody test kit . Plasma sample blood pretreated SMARTstim refer `` SMARTplasma '' . A total 1,600 blood sample collect tested use ELISA HIV HCV use FDA-approved test kit . The population include : - 1000 sample low risk individual ( blood donor ) 3 geographical location - 500 sample high risk individual risk HIV 2 geographical location - 100 know HIV seropositives This non-linked study ; , subject identifier associate collect blood . Subjects receive correspondence receive test result . If discordant result occur plasma SMARTplasma sample , sample retested . A Western Blot perform ELISA repeat reactive discordant sample . HCV test use FDA-approved assay may also perform use retained sample . Simple statistical method perform necessary analyze concordance result sample type ELISA assay . Secondarily , expect within scope study , show : - Using SMARTplasma adversely affect diagnostic specificity HIV and/or HCV antibody assay use ; i.e. , increase rate HIV HCV false positive result . - Using SMARTplasma adversely affect diagnostic sensitivity HIV and/or HCV antibody assay use ; i.e. , decrease number true positive sample . - Samples person early acute infection may show positive result use SMARTplasma , plasma test negative . - SMARTplasma sample use heparin EDTA collection tube correlate SMARTstim comparable . - SMARTplasma sample freeze show comparable result correlate SMARTplasma sample refrigerate .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Adults age 1864 , Are pregnant Not lifethreatening disease Not immunosuppressed ( HIV therapy allow ) Are able give consent , ( 6 ) appear healthy . Do meet inclusion criterion Are enrol HIV vaccine study , Who previously enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>HCV infection</keyword>
	<keyword>SMARTube</keyword>
	<keyword>SMARTplasma</keyword>
</DOC>